A dual monoclonal antibody-based sandwich ELISA for detection of potent vaccine immunogen against Coxsackievirus B1

Hao Chen; Rui Zhu; Yuanyuan Wu; Zhifeng Ke; Yubo Wu; Dongqing Zhang; Yuxiang Zou; Jiaying Wu; Xuejun Feng; Zhichao Yin; Mujin Fang; Ningshao Xia; Longfa Xu; Tong Cheng

doi:10.1016/j.virs.2025.11.007

PDF
Cite
Share

facebook

twitter

google

linkedin

Volume 40 Issue 6

December 2025

Citation: Hao Chen, Rui Zhu, Yuanyuan Wu, Zhifeng Ke, Yubo Wu, Dongqing Zhang, Yuxiang Zou, Jiaying Wu, Xuejun Feng, Zhichao Yin, Mujin Fang, Ningshao Xia, Longfa Xu, Tong Cheng. A dual monoclonal antibody-based sandwich ELISA for detection of potent vaccine immunogen against Coxsackievirus B1 .VIROLOGICA SINICA, 2025, 40(6) : 1050-1053. http://dx.doi.org/10.1016/j.virs.2025.11.007

A dual monoclonal antibody-based sandwich ELISA for detection of potent vaccine immunogen against Coxsackievirus B1

Hao Chen ^a,b ,
Rui Zhu ^a,b ,
Yuanyuan Wu ^a,b ,
Zhifeng Ke ^a,b ,
Yubo Wu ^a,b ,
Dongqing Zhang ^a,b ,
Yuxiang Zou ^a,b ,
Jiaying Wu ^a,b ,
Xuejun Feng ^a,b ,
Zhichao Yin ^c ,
Mujin Fang ^a,b ,
Ningshao Xia ^a,b ,
Longfa Xu ^{a,b
,,} ,
Tong Cheng ^{a,b
,,}

a. State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, China;
b. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China;
c. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, Beijing, China

Corresponding author: Longfa Xu, longfaxu@xmu.edu.cn
Tong Cheng, tcheng@xmu.edu.cn
Received Date: 24 July 2025
Accepted Date: 19 November 2025
Available online: 21 November 2025

Abstract

Highlights
1. The developed quantitative double-antibody sandwich ELISA supports the vaccine development, production, and quality control of CVB1 vaccine.
2. This method enables real-time monitoring of mature virion proportions during production, facilitating the optimization of production conditions.
3. Combining DAS-ELISA with density gradient centrifugation enables precise tracking of CVB1-M distribution, thereby guiding efficient purification.
4. The established DAS-ELISA offers rapid detection, low sample consumption, cost-effectiveness, and objective quantification.

Electronic Supplementary Material

10.1016j.virs.2025.11.007-ESM1.docx
References
1. Abedi, G.R., Watson, J.T., Nix, W.A., Oberste, M.S., Gerber, S.I., 2018. Enterovirus and Parechovirus Surveillance - United States, 2014-2016. MMWR Morb Mortal Wkly Rep, 67, 515-518.
2. Alhazmi, A., Nekoua, M.P., Mercier, A., Vergez, I., Sane, F., Alidjinou, E.K., Hober, D., 2023. Combating coxsackievirus B infections. Rev Med Virol, 33, e2406.
3. Baggen, J., Thibaut, H.J., Strating, J., Van Kuppeveld, F.J.M., 2018. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol, 16, 368-381.
4. Chong, P., Guo, M.S., Lin, F.H., Hsiao, K.N., Weng, S.Y., Chou, A.H., Wang, J.R., Hsieh, S.Y., Su, I.J., Liu, C.C., 2012. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One, 7, e49973.
5. Chu, P.Y., Tyan, Y.C., Chen, Y.S., Chen, H.L., Lu, P.L., Chen, Y.H., Chen, B.C., Huang, T.S., Wang, C.F., Su, H.J., Shi, Y.Y., Sanno-Duanda, B., Lin, K.H., Motomura, K., 2015. Transmission and Demographic Dynamics of Coxsackievirus B1. PLoS One, 10, e0129272.
6. Ferguson, M., Wood, D.J., Minor, P.D., 1993. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol, 74 ( Pt 4), 685-690.
7. Goren, A., Kaplan, M., Glaser, J., Isacsohn, M., 1989. Chronic neonatal coxsackie myocarditis. Arch Dis Child, 64, 404-406.
8. He, M.Z., Xu, L.F., Zheng, Q.B., Zhu, R., Yin, Z.C., Zha, Z.H., Lin, Y., Yang, L.S., Huang, Y., Ye, X.Z., et al., 2020. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. Cell Host & Microbe, 27, 249-261.
9. Hober, D., Alidjinou, E.K., 2018. Diabetes: Towards a coxsackievirus B-based vaccine to combat T1DM. Nat Rev Endocrinol, 14, 131-132.
10. Isaacs, S.R., Roy, A., Dance, B., Ward, E.J., Foskett, D.B., Maxwell, A.J., Rawlinson, W.D., Kim, K.W., Craig, M.E., 2023. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol, 11, 578-592.
11. Mone, K., Lasrado, N., Sur, M., Reddy, J., 2023. Vaccines against Group B Coxsackieviruses and Their Importance. Vaccines, 11, 274.
12. Pollack, A., Kontorovich, A.R., Fuster, V., Dec, G.W., 2015. Viral myocarditis--diagnosis, treatment options, and current controversies. Nat Rev Cardiol, 12, 670-680.
13. Tracy, S., Gauntt, C., 2008. Group B coxsackievirus virulence. Curr Top Microbiol Immunol, 323, 49-63.
14. Wang, T., Wang, C., Pang, L., Zhang, Y., Wang, S., Liang, X., Huang, Z., 2024. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles. Emerg Microbes Infect, 13, 2337665.
15. Xu, L., Zheng, Q., Zhu, R., Yin, Z., Yu, H., Lin, Y., Wu, Y., He, M., Huang, Y., Jiang, Y., et al., 2021. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host Microbe, 29, 448-462.
Proportional views

Figures(1)

PDF

Article Metrics

Article views(1868) PDF downloads(16) Cited by()

Proportional views

A dual monoclonal antibody-based sandwich ELISA for detection of potent vaccine immunogen against Coxsackievirus B1

Corresponding author: Longfa Xu, longfaxu@xmu.edu.cn

Corresponding author: Tong Cheng, tcheng@xmu.edu.cn

a. State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, China;
b. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China;
c. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, Beijing, China

Received Date: 24 July 2025
Accepted Date: 19 November 2025

Abstract: Highlights
1. The developed quantitative double-antibody sandwich ELISA supports the vaccine development, production, and quality control of CVB1 vaccine.
2. This method enables real-time monitoring of mature virion proportions during production, facilitating the optimization of production conditions.
3. Combining DAS-ELISA with density gradient centrifugation enables precise tracking of CVB1-M distribution, thereby guiding efficient purification.
4. The established DAS-ELISA offers rapid detection, low sample consumption, cost-effectiveness, and objective quantification.